Patient Support

Myrbetriq® (mirabegron) offers support for your patients with overactive bladder (OAB)

The Momentum Program offers co‑pay assistance and can help your patients take an active role in their treatment

Eligible patients can save up to $70 every month for a full year with a co‑pay card*

Momentum Savings Card

The Momentum Program includes:

  • Bladder‑friendly recipes and a list of foods to avoid
  • Exercises that can help manage OAB symptoms
  • A doctor discussion guide for patients to bring to their next appointment
  • Money‑saving opportunities* for Myrbetriq prescriptions
Download co‑pay card
Momentum Savings Card

Patients can activate their card online at momentumsavingscard.com or by phone at 1‑866‑666‑8244 to receive their 12 months of savings.

By activating this card, your eligible patients are also enrolling in Momentum, a program dedicated to providing recipes, exercise tips, and other helpful information.

*Subject to eligibility. Restrictions may apply. Patient is responsible for the first $20 plus any differential over $90 on each individual prescription. See eligibility restrictions, terms and conditions below.

Eligibility Restrictions,
Terms & Conditions

Astellas Savings & Support Opportunities

Astellas Pharma Support SolutionsSM | APSS

Astellas Pharma Support Solutions offers access services to help patients overcome challenges to accessing Myrbetriq® (mirabegron). APSS provides information regarding patient healthcare coverage options and financial assistance programs to help patients with financial needs. To learn more, visit AstellasPharmaSupportSolutions.com.

Checkmark

Benefit Verification

APSS can verify whether your patient's insurance plan(s) covers Myrbetriq, the stipulations of, and requirements for, coverage.

Checkmark

Prior Authorization Assistance

APSS can assist with drug prior authorizations when required by a patient's payer.

Astellas Patient Assistance Program

This program provides Myrbetriq® extended‑release tablets at no cost to patients who meet the program eligibility requirements. Astellas Pharma Support Solutions can determine whether a patient is eligible for enrollment. To learn more, visit AstellasPharmaSupportSolutions.com.

Checkmark

Prescription Delivery

Approved patients can receive direct shipments.

Checkmark

APSS eService

An online tool offering helpful alerts and email reminders.

Checkmark

Re‑enrollment

Simple re‑enrollment process for patients who continue to meet the eligibility criteria.

Patients may be eligible for the Astellas Patient Assistance Program if they meet the following criteria:

  • Be uninsured or have insurance that excludes coverage for Myrbetriq
  • Have a verifiable shipping address in the United States
  • Have been prescribed Myrbetriq for an FDA‑approved indication
  • Meet the program financial eligibility requirements

Helpful information on APSS and the Astellas Patient Assistance Program is available by either calling (800) 477‑6472 (Monday-Friday, 9 a.m.‑8 p.m. ET) or visiting AstellasPharmaSupportSolutions.com.

INDICATIONS AND USAGE

Myrbetriq® (mirabegron) is a beta‑3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

Do not use Myrbetriq® (mirabegron) in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Do not use Myrbetriq® (mirabegron) in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg). Worsening of hypertension was reported infrequently in Myrbetriq clinical trial patients with OAB.

In patients taking Myrbetriq, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.

Angioedema of the face, lips, tongue and/or larynx has been reported with Myrbetriq. In some cases angioedema occurred after the first dose. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue Myrbetriq and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co‑administered with Myrbetriq. Appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone.

In clinical trials, the most commonly reported adverse reactions (> 2% and > placebo) for Myrbetriq 25 mg and 50 mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs 7.6%), nasopharyngitis (3.5%, 3.9% vs 2.5%), urinary tract infection (4.2%, 2.9% vs 1.8%), and headache (2.1%, 3.2% vs 3.0%).

In postmarketing experience, the following events have also occurred: atrial fibrillation, nausea, constipation, diarrhea, and dizziness.

Please see accompanying complete Prescribing Information for Myrbetriq® (mirabegron).

References

1. Myrbetriq [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.

Important Safety Information,
Indications and Usage

INDICATIONS AND USAGE

Myrbetriq® (mirabegron) is a beta‑3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

Do not use Myrbetriq® (mirabegron) in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Do not use Myrbetriq® (mirabegron) in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet.

Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥ 180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg). Worsening of hypertension was reported infrequently in Myrbetriq clinical trial patients with OAB.

In patients taking Myrbetriq, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in Myrbetriq patients; however, Myrbetriq should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. Myrbetriq should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.

Angioedema of the face, lips, tongue and/or larynx has been reported with Myrbetriq. In some cases angioedema occurred after the first dose. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue Myrbetriq and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Since Myrbetriq is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates such as metoprolol and desipramine is increased when co‑administered with Myrbetriq. Appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone.

In clinical trials, the most commonly reported adverse reactions (> 2% and > placebo) for Myrbetriq 25 mg and 50 mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs 7.6%), nasopharyngitis (3.5%, 3.9% vs 2.5%), urinary tract infection (4.2%, 2.9% vs 1.8%), and headache (2.1%, 3.2% vs 3.0%).

In postmarketing experience, the following events have also occurred: atrial fibrillation, nausea, constipation, diarrhea, and dizziness.

Please see accompanying complete Prescribing Information for Myrbetriq® (mirabegron).